Management of Type IA Endoleak After EVAR by Explantation or Custom Made Fenestrated Endovascular Aortic Aneurysm Repair.


Journal

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
ISSN: 1532-2165
Titre abrégé: Eur J Vasc Endovasc Surg
Pays: England
ID NLM: 9512728

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 09 12 2019
revised: 08 06 2020
accepted: 26 10 2020
pubmed: 9 1 2021
medline: 25 5 2021
entrez: 8 1 2021
Statut: ppublish

Résumé

Proximal type 1 endoleak after endovascular abdominal aortic aneurysmal repair (EVAR) remains challenging to solve with no existing consensus. This work aims to compare two different surgical strategies to remedy type IA endoleak: endograft explantation (EXP) and aortic reconstruction or relining by custom made fenestrated EVAR (F-EVAR). A retrospective single centre analysis between 2009 and 2018 was conducted including patients treated for type IA endoleak after EVAR with either EXP or F-EVAR. The choice of surgical technique was based on morphological factors (F-EVAR eligibility), sac growth rate, emergency presentation and/or patient symptoms. Technical success, morbidity, secondary interventions, 30 day mortality, and long term survival according to Kaplan-Meier were determined for each group and compared. Fifty-nine patients (91% male, mean age 79 years) underwent either EXP (n = 26) or F-EVAR (n = 33) during the study period. The two groups were equivalent in terms of comorbidity and age at the time of procedure. The median time from initial EVAR was 60.4 months (34-85 months), with no difference between groups. The maximum aneurysm diameter was greater in the EXP group compared with the F-EVAR group, 86 mm (65-100) and 70 mm (60-80), respectively (p = .008). Thirty day secondary intervention (EXP: 11.5% vs. F-EVAR: 9.1%) and mortality (EXP: 3.8% vs. F-EVAR: 3.3%) rates did not differ between groups, while major adverse events at 30 days, defined by the current SVS guidelines, were lower in the F-EVAR group (2.4% vs. 13.6%; p = .016). One year survival rates were similar between the groups (EXP: 84.0% vs. F-EVAR: 86.6%). Open explantation and endovascular management with a fenestrated device for type IA endoleak after EVAR can be achieved in high volume centres with satisfactory results. F-EVAR is associated with decreased early morbidity. Open explantation is a relevant option because of acceptable outcomes and the limited applicability of F-EVAR.

Identifiants

pubmed: 33414067
pii: S1078-5884(20)30993-X
doi: 10.1016/j.ejvs.2020.10.033
pii:
doi:

Types de publication

Comparative Study Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

571-578

Informations de copyright

Copyright © 2020 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest S Haulon and J Sobocinski are consultants for Cook Medical.

Auteurs

Benoit Doumenc (B)

Service de chirurgie vasculaire, Centre de l'Aorte, CHU, Lille, France.

Thomas Mesnard (T)

Service de chirurgie vasculaire, Centre de l'Aorte, CHU, Lille, France; University of Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France.

Benjamin O Patterson (BO)

Department of Vascular Surgery, University Hospital Southampton, UK.

Richard Azzaoui (R)

Service de chirurgie vasculaire, Centre de l'Aorte, CHU, Lille, France.

Agathe De Préville (A)

Service de chirurgie vasculaire, Centre de l'Aorte, CHU, Lille, France.

Stephan Haulon (S)

Service de chirurgie vasculaire, Centre de l'Aorte, Hôpital Marie-Lannelongue, Le Plessis Robinson, France.

Jonathan Sobocinski (J)

Service de chirurgie vasculaire, Centre de l'Aorte, CHU, Lille, France; University of Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, Lille, France. Electronic address: jonathan.sobocinski@univ-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH